Paragon 28 Stock Performance Under the Microscope: Uncovering Investor Opportunities with The Spy Who Billed Me
July 18, 2023
☀️Trending News
Investors are increasingly intrigued by the performance of Paragon 28 ($NYSE:FNA) Inc.’s common stock on the market and The Spy Who Billed Me, a leading financial analysis firm, is uncovering the secret behind this surge in popularity. Paragon 28 Inc. is a company that has positioned itself as a pioneering leader in the field of foot and ankle surgery. This commitment to innovation, coupled with the development of revolutionary treatments, has resulted in increased interest in the company’s stock performance on the market. The Spy Who Billed Me is an experienced financial analysis firm that offers insight into the movements of market activity. Through extensive research and data analysis, they have been able to uncover the reasons behind Paragon 28 Inc.’s increasing success on the market.
Their findings have revealed that investors are attracted by the company’s dedication to growth and innovation, as well as its potential to become one of the leading players in their field. This analysis from The Spy Who Billed Me has opened up a number of opportunities for investors who are looking to capitalize on Paragon 28 Inc.’s potential. With a comprehensive understanding of the company’s stock performance on the market, investors can make more informed decisions regarding their investments. For those who are looking to invest with confidence, The Spy Who Billed Me is an invaluable source of information and analysis.
Share Price
Monday was a tough day for PARAGON 28 Inc. stock, with the company’s shares opening the day at $17.9 and closing at $17.7, representing a 1.0% decrease from the previous closing price of 17.9. Despite the dip in performance, investors may still be able to find opportunities in this stock. Enter The Spy Who Billed Me, a comprehensive stock analysis platform that provides investors with an in-depth look at the company’s financials, news, and other relevant data.
By using this platform, investors can get a better understanding of PARAGON 28’s financials and discover any potential opportunities within the stock. With the right information in hand, investors may be able to make wiser decisions when it comes to investing in PARAGON 28 stock. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Paragon 28. More…
| Total Revenues | Net Income | Net Margin |
| 192.05 | -67.14 | -20.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Paragon 28. More…
| Operations | Investing | Financing |
| -53.74 | -26.61 | 73.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Paragon 28. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 313.55 | 108.39 | 2.49 |
Key Ratios Snapshot
Some of the financial key ratios for Paragon 28 are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.5% | – | -32.6% |
| FCF Margin | ROE | ROA |
| -42.1% | -22.6% | -12.5% |
Analysis
At GoodWhale, we conducted an analysis to evaluate the wellbeing of PARAGON 28. To give you a better understanding of the risk, we have detected two risk warnings in the balance sheet and cashflow statement. If you want to learn more about these warnings, be sure to become a registered user. Once registered, you will be able to access all the details and insights of our analysis. More…
Peers
The company was founded in 2013 and is headquartered in San Diego, California. Paragon 28‘s competitors include Avra Medical Robotics Inc, Armm Inc, Implanet SA.
– Avra Medical Robotics Inc ($OTCPK:AVMR)
Avra Medical Robotics Inc is a medical technology company that focuses on the development and commercialization of robot-assisted surgery systems. The company’s products are designed to improve the safety and efficiency of surgical procedures. Avra Medical Robotics Inc has a market cap of 317.5k as of 2022, a Return on Equity of 231.87%. The company’s products are used in a variety of surgical procedures, including orthopedic, urological, and gynecological procedures.
– Armm Inc ($OTCPK:ARMM)
Implanet SA is a French company that designs, manufactures, and markets medical devices for orthopedic surgery. The company was founded in 2001 and has a market capitalization of 5.51 million as of 2022. The company’s return on equity is -114.56%.
The company’s products are used in the treatment of conditions such as osteoarthritis, degenerative disc disease, and scoliosis. The company’s products are sold in over 50 countries worldwide.
Summary
Paragon 28 Inc. is a company that has been gaining a lot of attention from investors due to its innovative foot and ankle surgery technology. Analyzing the market performance of Paragon 28 Inc. involves understanding the company’s financials and evaluating the profitability of its products and services. This involves analyzing the company’s balance sheet, income statements, cash flows, and other financial metrics to assess the company’s financial health. Investors should also examine the company’s competitive positioning by assessing the competitive environment and the company’s ability to compete with its rivals in the space.
Furthermore, investors should also consider the company’s potential returns in terms of dividends, share price, and other measures of financial performance. Ultimately, by conducting a thorough analysis of the market performance of Paragon 28 Inc. common stock, investors can make informed decisions about investing in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
